Clinical Efficacy and Safety Profile of Bimekizumab in Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
an hour ago
- #Bimekizumab Efficacy
- #Biologic Safety
- #Psoriasis Treatment
- Bimekizumab, a monoclonal antibody targeting IL-17A and IL-17F, showed superior efficacy over placebo and active biologics (adalimumab, ustekinumab, secukinumab) in treating psoriasis, with high response rates for PASI75, PASI90, PASI100, and IGA0/1 outcomes.
- Safety analysis indicated a higher risk of total treatment-emergent adverse events (TEAEs) compared to placebo but comparable to active controls, with increased risks of oral candidiasis and nasopharyngitis, while serious TEAEs, including inflammatory bowel disease (IBD), showed no significant difference.
- The study underscores the therapeutic advantage of dual IL-17A/F inhibition, though IBD risk assessment is limited by short follow-up and exclusion of IBD patients in trials, warranting cautious interpretation of long-term safety.